Ocata Therapeutics (OCAT) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Ocata Therapeutics (OCAT) Misses Q2 EPS by 1c

Ocata Therapeutics Provides Corporate Update for the Second Quarter of 2015

August 6, 2015 4:10 PM EDT

Call Scheduled for Today at 4:30 P.M.

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology, today provided a corporate update for the second quarter of 2015.

During the quarter, we made significant progress across multiple aspects of our business, most notably towards the initiation of a Phase 2 study in dry AMD and a pivotal study in SMD, said Paul K. Wotton, Ph.D., President and Chief Executive Officer. In addition, the completion of our financing has provided us with resources... More